Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 2.77
MACK's Cash-to-Debt is ranked lower than
97% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. MACK: 2.77 )
Ranked among companies with meaningful Cash-to-Debt only.
MACK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 1.46 Max: No Debt
Current: 2.77
Debt-to-Equity 0.46
MACK's Debt-to-Equity is ranked lower than
99.99% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. MACK: 0.46 )
Ranked among companies with meaningful Debt-to-Equity only.
MACK' s Debt-to-Equity Range Over the Past 10 Years
Min: -6.85  Med: -0.96 Max: 0.46
Current: 0.46
-6.85
0.46
Piotroski F-Score: 5
Altman Z-Score: -2.84
Beneish M-Score: 11.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -125.35
MACK's Operating Margin % is ranked higher than
51% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. MACK: -125.35 )
Ranked among companies with meaningful Operating Margin % only.
MACK' s Operating Margin % Range Over the Past 10 Years
Min: -2220.11  Med: -212.97 Max: -64.48
Current: -125.35
-2220.11
-64.48
Net Margin % 469.55
MACK's Net Margin % is ranked lower than
53% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. MACK: 469.55 )
Ranked among companies with meaningful Net Margin % only.
MACK' s Net Margin % Range Over the Past 10 Years
Min: -2284.59  Med: -209.06 Max: 469.55
Current: 469.55
-2284.59
469.55
ROA % 331.77
MACK's ROA % is ranked lower than
88% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. MACK: 331.77 )
Ranked among companies with meaningful ROA % only.
MACK' s ROA % Range Over the Past 10 Years
Min: -110.9  Med: -75.96 Max: 331.77
Current: 331.77
-110.9
331.77
ROC (Joel Greenblatt) % -704.13
MACK's ROC (Joel Greenblatt) % is ranked lower than
55% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. MACK: -704.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MACK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1458.87  Med: -719.41 Max: -468.88
Current: -704.13
-1458.87
-468.88
3-Year Revenue Growth Rate 33.60
MACK's 3-Year Revenue Growth Rate is ranked higher than
82% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. MACK: 33.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MACK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -31.2 Max: 33.6
Current: 33.6
0
33.6
3-Year EBITDA Growth Rate -11.30
MACK's 3-Year EBITDA Growth Rate is ranked lower than
66% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. MACK: -11.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MACK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -32.8 Max: -2.4
Current: -11.3
3-Year EPS without NRI Growth Rate -2.90
MACK's 3-Year EPS without NRI Growth Rate is ranked lower than
51% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. MACK: -2.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MACK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -38.1 Max: 1.3
Current: -2.9
0
1.3
GuruFocus has detected 4 Warning Signs with Merrimack Pharmaceuticals Inc $MACK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MACK's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

MACK Guru Trades in Q3 2016

Murray Stahl 25,000 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q4 2016

MACK Guru Trades in Q4 2016

Paul Tudor Jones 45,209 sh (New)
Murray Stahl 25,000 sh (unchged)
» More
Q1 2017

MACK Guru Trades in Q1 2017

Murray Stahl 25,000 sh (unchged)
Paul Tudor Jones 25,813 sh (-42.90%)
» More
Q2 2017

MACK Guru Trades in Q2 2017

Paul Tudor Jones 37,183 sh (+44.05%)
Murray Stahl 25,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MACK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:OCUL, NAS:AVXL, NAS:VTVT, NAS:VTL, NAS:CLSD, NAS:CASC, TSX:FRX, NAS:MNOV, NAS:COOL, NAS:ADXS, NAS:CNAT, NAS:SBPH, NAS:VSTM, NAS:OMED, NAS:FATE, NAS:ALBO, AMEX:OCX, NAS:MTEM, OTCPK:ARPO, NAS:SVRA » details
Traded in other countries:MP6N.Germany,
Headquarter Location:USA
Merrimack Pharmaceuticals Inc is a biotechnology company. It discovers, develops, and commercializes innovative medicines consisting of novel therapeutics paired with diagnostics to treat various types of cancer.

Merrimack Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.

Ratios

vs
industry
vs
history
PE Ratio 0.46
MACK's PE Ratio is ranked lower than
99.99% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. MACK: 0.46 )
Ranked among companies with meaningful PE Ratio only.
MACK' s PE Ratio Range Over the Past 10 Years
Min: 0.37  Med: 0.42 Max: 0.48
Current: 0.46
0.37
0.48
Price-to-Owner-Earnings 0.52
MACK's Price-to-Owner-Earnings is ranked lower than
99.99% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. MACK: 0.52 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MACK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0.41  Med: 0.47 Max: 0.54
Current: 0.52
0.41
0.54
PB Ratio 1.82
MACK's PB Ratio is ranked lower than
99.99% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. MACK: 1.82 )
Ranked among companies with meaningful PB Ratio only.
MACK' s PB Ratio Range Over the Past 10 Years
Min: 1.45  Med: 20.99 Max: 76.63
Current: 1.82
1.45
76.63
PS Ratio 2.14
MACK's PS Ratio is ranked higher than
93% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. MACK: 2.14 )
Ranked among companies with meaningful PS Ratio only.
MACK' s PS Ratio Range Over the Past 10 Years
Min: 1.68  Med: 9.8 Max: 20.46
Current: 2.14
1.68
20.46
EV-to-EBIT -0.95
MACK's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. MACK: -0.95 )
Ranked among companies with meaningful EV-to-EBIT only.
MACK' s EV-to-EBIT Range Over the Past 10 Years
Min: -20.4  Med: -6.1 Max: -0.5
Current: -0.95
-20.4
-0.5
EV-to-EBITDA -1.03
MACK's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. MACK: -1.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
MACK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.4  Med: -6.3 Max: -0.5
Current: -1.03
-21.4
-0.5
EV-to-Revenue 1.20
MACK's EV-to-Revenue is ranked higher than
83% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. MACK: 1.20 )
Ranked among companies with meaningful EV-to-Revenue only.
MACK' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.7  Med: 10.9 Max: 26.1
Current: 1.2
0.7
26.1
Current Ratio 2.45
MACK's Current Ratio is ranked lower than
95% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. MACK: 2.45 )
Ranked among companies with meaningful Current Ratio only.
MACK' s Current Ratio Range Over the Past 10 Years
Min: 0.43  Med: 1.75 Max: 4.51
Current: 2.45
0.43
4.51
Quick Ratio 2.45
MACK's Quick Ratio is ranked lower than
96% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. MACK: 2.45 )
Ranked among companies with meaningful Quick Ratio only.
MACK' s Quick Ratio Range Over the Past 10 Years
Min: 0.28  Med: 1.71 Max: 4.51
Current: 2.45
0.28
4.51
Days Inventory 1.00
MACK's Days Inventory is ranked lower than
99% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. MACK: 1.00 )
Ranked among companies with meaningful Days Inventory only.
MACK' s Days Inventory Range Over the Past 10 Years
Min: 1  Med: 7614.61 Max: 14746.79
Current: 1
1
14746.79
Days Sales Outstanding 0.18
MACK's Days Sales Outstanding is ranked higher than
81% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. MACK: 0.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
MACK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.18  Med: 56.03 Max: 300.77
Current: 0.18
0.18
300.77
Days Payable 699.65
MACK's Days Payable is ranked higher than
92% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. MACK: 699.65 )
Ranked among companies with meaningful Days Payable only.
MACK' s Days Payable Range Over the Past 10 Years
Min: 9.02  Med: 100.35 Max: 40062.72
Current: 699.65
9.02
40062.72

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.30
MACK's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. MACK: -8.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MACK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -111.1  Med: -8.3 Max: 0
Current: -8.3
-111.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.87
MACK's Price-to-Net-Cash is ranked lower than
99.99% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. MACK: 6.87 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MACK' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 5.77  Med: 457.89 Max: 910
Current: 6.87
5.77
910
Price-to-Net-Current-Asset-Value 5.66
MACK's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. MACK: 5.66 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MACK' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.75  Med: 26.01 Max: 47.27
Current: 5.66
4.75
47.27
Price-to-Tangible-Book 1.84
MACK's Price-to-Tangible-Book is ranked lower than
99.99% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. MACK: 1.84 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MACK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.54  Med: 17.96 Max: 34.37
Current: 1.84
1.54
34.37
Price-to-Median-PS-Value 0.22
MACK's Price-to-Median-PS-Value is ranked higher than
94% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. MACK: 0.22 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MACK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18  Med: 1.11 Max: 1.66
Current: 0.22
0.18
1.66
Earnings Yield (Greenblatt) % -103.09
MACK's Earnings Yield (Greenblatt) % is ranked lower than
79% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. MACK: -103.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MACK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -211.9  Med: -16.4 Max: -4.9
Current: -103.09
-211.9
-4.9

More Statistics

Revenue (TTM) (Mil) $89.31
EPS (TTM) $ 31.50
Beta1.95
Short Percentage of Float22.11%
52-Week Range $11.30 - 67.90
Shares Outstanding (Mil)132.79

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 202 316
EPS ($) -0.93 -0.42
EPS without NRI ($) -0.93 -0.42
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for MACK

Headlines

Articles On GuruFocus.com
Merrimack Announces Date of One-for-Ten Reverse Stock Split Aug 31 2017 
Merrimack Augments Executive Team with Appointment of Jean Franchi as Chief Financial Officer Aug 14 2017 
Merrimack Reports Second Quarter 2017 Financial Results Aug 09 2017 
Merrimack Announces Timing of Second Quarter 2017 Investor Conference Call Aug 02 2017 
Merrimack Appoints Thomas Needham as Chief Business Officer Jul 24 2017 
Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in Fir Jun 19 2017 
Merrimack Announces Expansion of Senior Management Team with Appointment of Sergio Santillana as Chi Jun 08 2017 
Merrimack Announces Management Change May 25 2017 
Merrimack Reports First Quarter 2017 Financial Results May 10 2017 
Merrimack Announces Timing of First Quarter 2017 Investor Conference Call May 02 2017 

More From Other Websites
Is It Time To Buy Merrimack Pharmaceuticals Inc (MACK)? Sep 20 2017
Today's Research Reports on Trending Tickers: American Superconductor and Merrimack Pharmaceuticals Sep 07 2017
Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers Aug 31 2017
Merrimack Announces Date of One-for-Ten Reverse Stock Split Aug 31 2017
Merrimack Augments Executive Team with Appointment of Jean Franchi as Chief Financial Officer Aug 14 2017
Edited Transcript of MACK earnings conference call or presentation 9-Aug-17 12:30pm GMT Aug 13 2017
Merrimack (MACK) Q2 Loss Wider than Expected, Stock Falls Aug 10 2017
Merrimack misses 2Q profit forecasts Aug 09 2017
Merrimack's (MACK) Reports Wider-than-Expected Q2 Loss Aug 09 2017
Merrimack Reports Second Quarter 2017 Financial Results Aug 09 2017
Investor Network: Merrimack Pharmaceuticals, Inc. to Host Earnings Call Aug 09 2017
Merrimack Announces Timing of Second Quarter 2017 Investor Conference Call Aug 02 2017
ETFs with exposure to Merrimack Pharmaceuticals, Inc. : August 1, 2017 Aug 01 2017
What's in the Cards for Merrimack (MACK) in Q2 Earnings? Jul 28 2017
Merrimack Appoints Thomas Needham as Chief Business Officer Jul 24 2017
Edited Transcript of MACK earnings conference call or presentation 1-Mar-17 1:30pm GMT Jun 27 2017
Biotech Industry Showing Signs of a Revival in 2017: Today's Research on Moleculin Biotech and... Jun 22 2017
These 3 Biotechs Have Been Crushed; Is It Time to Bargain Shop? Jun 21 2017
Merrimack Completes Enrollment in Phase II Study for MM-141 Jun 20 2017
Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in... Jun 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}